CREATE Medicines

High-Level Overview

CREATE Medicines is a clinical-stage biotechnology company (formerly Myeloid Therapeutics) pioneering in vivo multi-immune programming using a proprietary mRNA-lipid nanoparticle (LNP) platform to directly program immune cells like T cells, myeloid cells, and NK cells inside the body.[1][2][4] It develops scalable, repeat-dose, off-the-shelf immunotherapies targeting solid tumors (e.g., HER2, TROP2, GPC3-positive cancers), autoimmunity, and fibrosis, with MT-304 as a lead HER2 multi-immune CAR for breast cancer and the first RNA retrotransposon-based in vivo CAR-T for B-cell depletion.[1][2] The company serves patients with hard-to-treat cancers and immune disorders, solving the limitations of ex vivo cell therapies by enabling precise, tolerable in-body immune cell engineering validated in over 40 patients.[1][3]

Origin Story

CREATE Medicines originated as Myeloid Therapeutics and rebranded in late 2025 to reflect its expanded focus on transformative RNA-based in vivo multi-immune programming.[1] Led by CEO Daniel Getts, Ph.D., who highlighted clinical proof in over 40 patients for tolerable, repeat-dose immune programming, and Chief Scientific Officer Robert Hofmeister, Ph.D., who advanced the RetroT platform, the company evolved from early mRNA-LNP work to next-generation RNA technologies like all-RNA gene writing.[1][2] Pivotal moments include positive first-in-human results for in vivo CAR therapies and the October 2025 unveiling of RetroT at the Cold Spring Harbor Laboratory Meeting, demonstrating site-specific CAR integration in T cells without DNA breaks or viral vectors.[2][3][5]

Core Differentiators

• In vivo multi-immune programming platform: Uses targeted mRNA-LNP for selective activation of T, myeloid, and NK cells directly in the body, enabling scalable, off-the-shelf therapies unlike ex vivo approaches requiring cell extraction.[1][2][4]
• RetroT all-RNA gene writing: Fully RNA-encoded system leveraging human LINE-1 machinery for precise, durable, site-specific integration of multi-kb payloads (e.g., CAR constructs) in T cells, avoiding double-strand breaks, viral vectors, or DNA templates for superior safety and re-dosability.[2][5]
• Clinical validation and pipeline speed: Proven tolerability in >40 patients; most advanced in RNA-based in vivo CARs for solid tumors (HER2, TROP2, GPC3) and B-cell depletion, with preclinical multi-lineage programs in oncology, autoimmunity, and fibrosis.[1][3]
• RNA engineering advantages: Supports repeat dosing, permanent CAR integration via retrotransposons, and broader immune lineage targeting for deeper, durable responses.[1][2]

Role in the Broader Tech Landscape

CREATE Medicines rides the wave of RNA therapeutics and in vivo cell programming, capitalizing on mRNA-LNP successes from COVID vaccines to enable "off-the-shelf" immunotherapies that bypass manufacturing bottlenecks of personalized ex vivo CAR-T cells.[1][2] Timing is ideal amid surging demand for scalable cancer and autoimmune treatments, with market forces like rising solid tumor challenges (where ex vivo therapies falter) and RNA tech maturation favoring their approach.[1][5] By influencing the ecosystem through human-validated platforms and breakthroughs like RetroT, CREATE accelerates a shift to in-body engineering, potentially lowering costs and expanding access beyond elite centers.[2]

Quick Take & Future Outlook

Next steps include advancing MT-304 into deeper breast cancer trials, launching the first RNA retrotransposon CAR-T for B-cell depletion, and expanding preclinical multi-lineage programs across oncology and immunology.[1][2] Trends like RNA gene writing, precise LNPs, and multi-immune synergies will propel growth, positioning CREATE to dominate in vivo CARs as safety data solidifies. Its influence may evolve from pioneer to standard-setter, redefining immunotherapy scalability and tying back to its core mission of transforming hard-to-treat diseases through body-native immune reprogramming.[1]